Clinical Trial Update: Nimotuzumab for Recurrent Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for nimotuzumab in recurrent nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer
• Nasopharyngeal Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Recurrent Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN